ARCUTIS BIOTHERAPEUTICS, INC. Interest Income, Other
ARCUTIS BIOTHERAPEUTICS, INC. (ARQT) reported Interest Income, Other of $2.27 million for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-05-06.
Financial Statements › Income Statement › Other Income
us-gaap:InterestIncomeOther · last filed 2026-05-06
- ARCUTIS BIOTHERAPEUTICS, INC. interest income, other for the quarter ending 2026-03-31 was $2.27M, a 10.33% decline year-over-year.
- ARCUTIS BIOTHERAPEUTICS, INC. interest income, other for the quarter ending 2025-03-31 was $2.54M.
- ARCUTIS BIOTHERAPEUTICS, INC. interest income, other for fiscal 2025 was $8.90M, a 44.83% decline from fiscal 2024.
- ARCUTIS BIOTHERAPEUTICS, INC. interest income, other for fiscal 2024 was $16.13M, a 28.83% increase from fiscal 2023.
- ARCUTIS BIOTHERAPEUTICS, INC. interest income, other for fiscal 2023 was $12.52M.
| Period end | Interest Income, Other 3 month | Interest Income, Other 12 month |
|---|---|---|
| 2026-03-31 | $2.27M 10-Q · filed 2026-05-06 | |
| 2025-12-31 | $8.90M 10-K · filed 2026-02-25 | |
| 2025-03-31 | $2.54M 10-Q · filed 2026-05-06 | |
| 2024-12-31 | $16.13M 10-K · filed 2026-02-25 | |
| 2023-12-31 | $12.52M 10-K · filed 2026-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 |